Docoh
Loading...

SEEL Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

Company profile

Ticker
SEEL
Exchange
CEO
Raj Mehra
Employees
Incorporated
Location
Fiscal year end
Former names
APRICUS BIOSCIENCES, INC., NEXMED INC
SEC CIK
IRS number
870449967

SEEL stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

30 Apr 21
27 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 38.69M 38.69M 38.69M 38.69M 38.69M 38.69M
Cash burn (monthly) (positive/no burn) (positive/no burn) 5.54M 2.49M 3.75M 2.15M
Cash used (since last report) n/a n/a 21.49M 9.66M 14.56M 8.33M
Cash remaining n/a n/a 17.19M 29.03M 24.13M 30.36M
Runway (months of cash) n/a n/a 3.1 11.7 6.4 14.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Mar 21 Mehra Raj Stock Option Common Stock Grant Aquire A No No 4.31 1,150,000 4.96M 1,150,000
6 Jan 21 O'Connor Daniel J. Stock Option Common Stock Grant Aquire A No No 1.35 16,000 21.6K 16,000
6 Jan 21 Judith Dunn Stock Option Common Stock Grant Aquire A No No 1.35 16,000 21.6K 16,000
6 Jan 21 Lian Brian Stock Option Common Stock Grant Aquire A No No 1.35 16,000 21.6K 16,000
6 Jan 21 Pascoe Richard W Stock Option Common Stock Grant Aquire A No No 1.35 16,000 21.6K 16,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

34.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 71 1 +7000.0%
Opened positions 70 1 +6900.0%
Closed positions 0 32 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 179.96M 3.51M +5021.2%
Total shares 27.21M 2.22M +1123.4%
Total puts 293.5K 0 NEW
Total calls 103.8K 0 NEW
Total put/call ratio 2.8
Largest owners
Shares Value Change
IVZ Invesco 3.46M $17.29M NEW
Vanguard 2.92M $14.58M NEW
LGND Ligand Pharmaceuticals 2.22M $3.51M 0.0%
Mangrove Partners 2.16M $10.79M NEW
Mirae Asset Global Investments 1.89M $9.43M NEW
Acuta Capital Partners 1.72M $8.58M NEW
Uniplan Investment Counsel 1.53M $7.63M NEW
Marshall Wace North America 1.45M $7.22M NEW
Gendell Jeffrey L 1.23M $6.11M NEW
BLK Blackrock 1.19M $5.95M NEW
Largest transactions
Shares Bought/sold Change
IVZ Invesco 3.46M +3.46M NEW
Vanguard 2.92M +2.92M NEW
Mangrove Partners 2.16M +2.16M NEW
Mirae Asset Global Investments 1.89M +1.89M NEW
Acuta Capital Partners 1.72M +1.72M NEW
Uniplan Investment Counsel 1.53M +1.53M NEW
Marshall Wace North America 1.45M +1.45M NEW
Gendell Jeffrey L 1.23M +1.23M NEW
BLK Blackrock 1.19M +1.19M NEW
Ikarian Capital 718.28K +718.28K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abnormal, agonist, Allergan, animal, antidepressant, Atopic, autophagy, Avenue, biocompatibility, Book, borrowed, borrowing, Brexit, called, Chemistry, Chemoattractant, Chilcott, CMC, collateralized, complicated, contest, controversy, conventional, counterparty, culture, DEA, death, decision, devastating, disaccharide, dismissal, DNA, domain, dopamine, EB, editing, eighteen, emphasize, eventually, expedite, expedited, Experimental, explore, explored, feature, free, gathered, GMP, goal, greatly, Harvard, Healey, healthy, Hedging, hereof, histamine, holder, human, hundred, hydrochloride, hydrocholoride, IIa, implicit, inhibit, instrument, interaction, intron, Javelin, Joseph, kDa, lawsuit, leave, legacy, licensure, Lind, lysosomal, Machado, mandatorily, mandatory, manifested, mechanism, methylation, mice, misfolded, misuse, Mitigation, molecular, monotherapy, muscle, mutant, mutated, NACore, nasal, nonamyloid, nonclinical, NY, occupy, oral, orally, Orange, outweigh, parallel, Park, pathologic, pathological, pathway, penalty, penetrate, Phenomenon, physiological, pluripotent, possession, potent, prepay, prepayment, procurement, promissory, propagation, proven, quotient, rapid, rationale, rationally, Raynaud, reconsider, redeemable, referenced, refractory, repayment, revocation, risky, ROU, School, scleroderma, secondary, seeding, shorter, simultaneously, solution, sound, SPA, speculative, spray, startup, subordinated, substance, Subtopic, suggest, suit, TFEB, Traditionally, Transcription, true, twenty, UK, undergoing, underway, USP, vacate, vacated, volunteer, waived, Warner, Wyeth
Removed: AB, absolute, accounted, APA, arrive, assessment, assigned, attest, avoid, capacity, carried, charter, close, conceived, dated, detail, detection, deteriorate, Diego, Disclosing, disposition, essentially, estate, exceeding, exchangeable, expired, float, formal, framework, half, holding, incorporate, indemnification, ineligible, Instruction, intangible, issuer, ix, Jaffray, KPMG, location, modification, nominal, occurring, operated, overseen, Pertain, Piper, presentation, President, pressure, primary, prioritizing, privately, promulgated, PTSD, qualifying, real, recapitalization, record, register, reimburse, reliability, remeasure, removed, renew, renewed, Reservation, run, San, scenario, shareholder, short, simple, Sponsoring, stated, sublease, subleased, supplemental, tangible, thousand, topical, Treadway, Trump, turnover, unpaid